Analyst Note
| Alex Morozov, CFA |We are likely to slightly raise our fair value estimate for narrow-moat Thermo Fisher Scientific following the release of fourth-quarter and full-year results. The company delivered strong performance, supported by $3.2 billion in COVID-19 pandemic response revenue in the quarter alone. We continue to see the shares as overvalued.